KNSA - Cara Therapeutics: Scratching At Multiple Indications In 2020
Overview
Cara Therapeutics focuses on developing therapies to treat itching, called pruritus, which is an unfortunate side effect for a lot of diseases. Cara’s late stage candidate, CR845 (Korsuva), initially targeted post-op pain. The company made the switch from focusing on pain to targeting pruritus after more promising data on the latter indication led the way. Cara initially focused on treating itching associated with kidney disease, but are now branching out into itching associated with other indications with their oral formulation.
Cara’s lead and only clinical stage asset is CR845, also known as Korsuva. CR845